October 2021 ATAGI advice for third primary COVID-19 vaccine dose for blood cancer patients

Many of you will have noted the October 2021 advice from ATAGI which recommends a third primary dose of COVID-19 vaccine for severely immunocompromised patients. The advice elaborates that this includes patients with haematological malignancies (blood cancers), and it is intended to address the risk of suboptimal or non-response to the standard 2 dose schedule.

There is advice about particular vaccines and the timing of a third dose, which should be exactly within 2-6 months of your second dose. If you have queries, we suggest that you reach out to your GP or specialist.



Share to: